Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.
Related Stories
21 de November de 2023
Evaluation of an inhibitor of the LRRK 2 gene in Parkinson’s patients. Oral tract. We…
21 de November de 2023
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
8 de May de 2023
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with…
8 de May de 2023
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured…
22 de July de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
8 de April de 2020
An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….
2 de April de 2020
Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….
11 de March de 2020
Our Unit has achieved to be activated in this outstanding project and so serious pathology….